A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer

NCT06047860 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Tumor
Refractory Tumor

Interventions

RADIATION: Radiotherapy
DRUG: PD-1/PD-L1 inhibitor
DRUG: Granulocyte-macrophage colony-stimulating factor subcutaneous injection
DRUG: Interleukin 2 subcutaneous injection
DRUG: Endostatin

Sponsor

Second Affiliated Hospital of Soochow University